期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽基肽酶Ⅳ抑制剂的研究进展 被引量：2

Advances in dipeptidyl peptidase-Ⅳ inhibitors
原文传递
导出
摘要 二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂是一种新的糖尿病治疗药物,基础研究证实它除了促进胰岛素分泌之外,还可调节炎症反应、对抗氧化应激、保护胰岛β细胞、对抗血管损伤、改善胰岛素抵抗,降糖机制多样。临床上无论单用还是与其他药物联合,均取得良好的降糖效果,且不良反应轻微。 Dipeptidyl peptidase IV （DPP-IV） inhibitors are new oral drugs for the treatment of diabetes. In addition to increasing insulin secretion, DPP-IV inhibitors may regulate the inflammatory response, fight against oxidative stress and vascular injury, protect islet beta-cells, improve insulin resistance, and so on. DPP-IV inhibitors are effective in reducing blood glucose levels, either alone or in combination with other drugs.
作者 姜志华 陈海冰
机构地区 上海电力医院内科 上海交通大学附属第六人民医院内分泌代谢科
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2011年第11期847-851,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 胰高血糖素样肽1 糖尿病 二肽基肽酶 glucogon-like peptide 1 diabetes dipeptidyl peptidase
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献3

二级参考文献99

  • 1蔡乐,朱珠,王强,刘新月.胰岛素类似物与新型降糖激素类药物[J].中国新药杂志,2007,16(6):432-437. 被引量：26
  • 2International Diabetes Federation.Foreword of the Diabetes Atlas(4th edition)[EB/OL].(2009-10-01)[2010-6-16].http://www.diabetesatlas.org/content/foreword-0.
  • 3VanDeKoppel S,Choe HM,Sweet BV.Mana ged care perspective on three new agents for type 2 diabetes[J].J Manag Care Pharm,2008,14(4):363-380.
  • 4Freeman JS.Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus[J].Cleve Clin J Med,2009,76(Suppl 5):S12-S19.
  • 5Todd JF,Bloom SR.Incretins and other peptides in the treatment of diabetes[J].Diabet Med,2007,24(3):223-232.
  • 6Neumiller JJ.Differential chemistry(structure),mechanism of action,and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors[J].J Am Pharm Assoc,2009,49(Suppl 1):S16-S29.
  • 7Tahrani AA,Piya MK,Barnett AH.Saxagliptin:a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus[J].Adv Ther,2009,26(3):249-262.
  • 8Demuth HU,McIntosh CH,Pederson RA.Type 2 diabetestherapy with dipeptidyl peptidase Ⅳ inhibitors[J].Biochem Biophys Acta,2005,1751(1):33-44.
  • 9Kirby M,Yu DM,O'Connor S,et al.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition[J].Clin Sci(Lond),2009,118(1):31-41.
  • 10Kendall DM,Cuddihy RM,Bergenstal RM.Clinical application of incretin-based therapy:therapeutic potential patient selection and clinical use[J].Ear J Intern Med,2009,20(Suppl 2):S329-S339.

共引文献21

同被引文献19

  • 1HOROWITZ M,RAYNER CK,JONES KL,et al.Mechanisms and clinical efficacy of lixisenatide for the management of type 2diabetes[J].Adv Ther,2013,30(2):81-101.
  • 2YANG W,PAN CY,TOU C,et al.Efficacy and safety of saxagliptin added to metformin in Asian people with type 2diabetes mellitus:a randomized controlled trial[J].Diabetes Res Clin Pract,2011,94(2):217-224.
  • 3FORST T,UHLIG-LASKE B,RING A,et al.Linagliptin(BI1356),a potent and selective DPP-4 inhibitor,is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes[J].Diabet Med,2010,27(12):1409-1419.
  • 4TASKINEN MR,ROSENSTOCK J,TAMMINEN I,et al.Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes:a randomized,double-blind,placebo-controlled study[J].Diabetes Obes Metab,2011,13(1):65-74.
  • 5HAAK T,MEINICKE T,JONES R,et al.Initial combination of linagliptin and metformin improves glycaemic control in type 2diabetes:a randomized,double-blind,placebo-controlled study[J].Diabetes Obes Metab,2012,14(6):565-574.
  • 6ROSS SA,RAFEIRO E,MEINICKE T,et al.Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin:a randomised,double-blind,placebo-controlled trial[J].Curr Med Res Opin,2012,28(9):1465-1474.
  • 7THOMAS L,ECKHARDT M,LANGKOPF E,et al.(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI 1356),a novel xanthine-based dipeptidyl peptidase 4inhibitor,has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors[J].J Pharmacol Exp Ther,2008,325(1):175-182.
  • 8HUTTNER S,GRAEFE-MODY EU,WITHOPF B,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of single oral doses of BI 1356,an inhibitor of dipeptidyl peptidase4,in healthy male volunteers[J].Clin Pharmacol,2008,48(10):1171-1178.
  • 9Anon.National institute for health and clinical excellence.Liraglutide for the treatment of type 2 diabetes mellitus[EB/OL].(2012-10-01)[2011-09-20].http://publications.nice.org.uk./liraglutide for the treatment of type 2 diabetes mellitus ta203/consideration of the evidence summary of appraisal committees key conclusions.
  • 10OWENS DR,SWALLOW R,DUGI KA,et al.Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea:a24-week randomized study[J].Diabet Med,2011,28(13):52-61.

引证文献2

二级引证文献47

中国新药与临床杂志
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部